AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
July 31, 2020- On May 8, 2020, AbbVie Completed its Acquisition of Allergan, Significantly Expanding and Diversifying AbbVie's Revenue Base with New Therapeutic Areas, Enhancing Long-Term Growth Potential, and Enabling Investment in Innovation for each of its Therapeutic Categories
-
July 29, 2020- Phase 3 ADVANCE trial evaluating atogepant meets primary endpoint of statistically significant reduction from baseline in mean monthly migraine days, compared to placebo, for all doses evaluated across a 12-week treatment period
-
July 28, 2020- Positive top-line results show upadacitinib (15 mg and 30 mg) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in adult and adolescent patients with moderate to severe atopic dermatitis versus placebo plus TCS[1]
-
July 21, 2020- Upadacitinib (15 mg and 30 mg) monotherapy showed significant improvement in skin clearance and reduction in itch at week 16 in adult and adolescent patients with moderate to severe atopic dermatitis versus placebo[1]
-
July 09, 2020- Updated Label Now Includes Pediatric Patients with Lower Limb Spasticity Caused by Cerebral Palsy
-
June 23, 2020- Submission is based on results of more than five years of follow-up data from the Phase 3 iNNOVATE clinical trial evaluating IMBRUVICA in combination with rituximab for patients with WM. This is the longest follow-up data available for a BTK inhibitor in WM
-
June 22, 2020- Application Seeks to Extend Use of BOTOX® for Patients 5 to 17 Years Old
-
June 18, 2020- Top-line results from a Phase 3 study evaluating RINVOQ in moderate to severe atopic dermatitis in adults and adolescents show both doses of upadacitinib (15 mg and 30 mg) monotherapy met all primary and secondary endpoints versus placebo[1]
-
June 17, 2020
-
June 15, 2020JUVÉDERM® VOLUMA™ XC IS FIRST AND ONLY PRODUCT OF ITS KIND APPROVED BY THE FDA FOR USE IN THE CHIN
-
June 15, 2020- Real-world studies assessed persistence of BOTOX® (onabotulinumtoxinA) versus calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs)
-
June 13, 2020- Phase 3 VIALE-A study showed a 34 percent reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared to azacitidine plus placebo
-
June 12, 2020- New head-to-head data from the IMMerge Phase 3b open-label study show SKYRIZI demonstrated superiority to COSENTYX at week 52, with 66 percent of SKYRIZI patients achieving completely clear skin (PASI 100) versus 40 percent of COSENTYX patients[1]
-
June 10, 2020- Data show the clinical activity of ABBV-3373 and support advancing the development of the platform in rheumatoid arthritis and initiating clinical studies in other immune-mediated diseases[1]
-
June 10, 2020- AbbVie and Genmab entered into a broad collaboration to jointly develop and commercialize three of Genmab's next-generation bispecific antibody products, including epcoritamab
-
June 06, 2020- In SELECT-CHOICE, RINVOQ™ (upadacitinib, 15 mg, once daily) met both the primary (non-inferiority) and key secondary (superiority) endpoints compared to ORENCIA® (abatacept) on change from baseline in DAS28-CRP at week 12 in patients with rheumatoid arthritis and inadequate response to biologic DMARDs[1]
-
June 04, 2020- Long-term results from the SELECT-COMPARE and SELECT-MONOTHERAPY studies showed that RINVOQ™ (upadacitinib, 15 mg) continued to improve signs and symptoms in patients with rheumatoid arthritis through 72 and 84 weeks, respectively[1,2]
-
June 01, 2020- Submissions supported by two Phase 3 studies in which RINVOQ demonstrated improved joint outcomes, physical function and skin symptoms, with a greater proportion of patients achieving minimal disease activity versus placebo* [1,2]
-
June 01, 2020Connecting with patients to participate in device tracking enables them to be contacted in the event of a safety issue
-
May 29, 2020- Uterine fibroids are the most common type of benign tumor in women of reproductive age[1]
-
May 27, 2020- First presentation of the SELECT-CHOICE study evaluating efficacy and safety of RINVOQ™ (upadacitinib) compared to abatacept in patients with moderate to severe active rheumatoid arthritis
-
May 15, 2020- AbbVie to present more than 30 abstracts from studies of its on-market and investigational medicines from its oncology portfolio and pipeline across six tumor types at the EHA Annual Congress
-
May 08, 2020- Creates biopharmaceutical company with leadership positions in key therapeutic areas: Immunology, Hematologic Oncology, Neuroscience, and Allergan Aesthetics
-
May 01, 2020- Reports First-Quarter Diluted EPS of $2.02 on a GAAP Basis; Adjusted Diluted EPS of $2.42
-
April 21, 2020- IMBRUVICA plus rituximab demonstrated superior progression-free survival against the chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL)
-
April 02, 2020
-
March 31, 2020- AbbVie partners with International Medical Corps, Direct Relief and Feeding America to increase healthcare capacity, supply critical equipment and deliver food and essential supplies
-
March 23, 2020- VIALE-A study demonstrated statistically significant improvement in the primary endpoints of overall survival (OS) and composite complete remission rate (CR + CRi)
-
March 12, 2020- VENCLYXTO® plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by the European Commission (EC) for patients with previously untreated chronic lymphocytic leukemia (CLL)
-
March 09, 2020- Unconfirmed media reports from China claim Kaletra/Aluvia (lopinavir/ritonavir) is effective in COVID-19 treatment.
-
March 06, 2020- MAVIRET now available in the EU as an 8-week treatment option for treatment-naïve, chronic hepatitis C (HCV) patients without cirrhosis or with compensated cirrhosis, regardless of genotype*
-
February 28, 2020- Study did not demonstrate statistically significant improvement in the primary endpoint of overall survival (OS) (Hazard Ratio [HR]=0.75, [95% CI 0.52 - 1.07], p=0.11)
-
February 20, 2020
-
February 19, 2020
-
February 07, 2020- Reports Full-Year Diluted EPS of $5.28 on a GAAP Basis, an Increase of 44.3 Percent; Adjusted Diluted EPS of $8.94, an Increase of 13.0 Percent
-
February 05, 2020- In this large Phase 3 study, RINVOQ™ (upadacitinib; 15 mg and 30 mg, once daily) met the primary endpoint of ACR20 response at week 12 versus placebo in adult patients with active psoriatic arthritis[1]
-
January 31, 2020- If approved by the European Commission (EC), MAVIRET will be the only pan-genotypic (GT1-6) 8-week treatment option for treatment-naïve, chronic hepatitis C (HCV) patients, without cirrhosis or with compensated cirrhosis
-
January 31, 2020- If approved by the European Commission (EC), VENCLYXTO® plus obinutuzumab would be the first chemotherapy-free, combination regimen given with a fixed duration for patients with previously untreated chronic lymphocytic leukemia (CLL)
-
January 27, 2020Agreements Contingent on FTC and European Commission Approval and Completion of AbbVie's Pending Acquisition of Allergan
-
January 14, 2020- SKYRIZI™ (risankizumab) met both primary and all secondary endpoints in a head-to-head, open-label study versus Cosentyx® (secukinumab)[1]
-
December 18, 2019- Approval supported by data from the pivotal Phase 3 SELECT rheumatoid arthritis program evaluating nearly 4,400 patients[1-5]
-
December 08, 2019- Four-year updated analysis from the MURANO trial showed an 81% reduction in the risk of disease progression or death in patients treated with VENCLEXTA®/VENCLYXTO® (venetoclax) plus rituximab (VenR) and higher rates of minimal residual disease (MRD)-negativity compared to bendamustine plus rituximab (BR)[1]
-
December 07, 2019- With extended follow-up of up to 7.5 years, treatment with IMBRUVICA early on in therapy demonstrated higher rates of progression-free survival and complete response
-
December 07, 2019- Follow-up data from Phase 3 E1912 study (abstract #33) evaluating IMBRUVICA in combination with rituximab versus standard chemoimmunotherapy (FCR) showed that previously untreated patients (aged 70 or younger) with CLL lived longer and with sustained benefit, with superior progression-free survival and overall survival - two critical measures in oncology treatment success
-
December 07, 2019- New results from the Phase 2 CAPTIVATE clinical trial show the potential of this fixed-duration, combination therapy for CLL patients starting treatment for the first time
-
November 21, 2019- AbbVie will present more than 40 abstracts featuring data from approved and investigational medicines
-
November 12, 2019
-
November 12, 2019- In SELECT-AXIS 1, RINVOQ™ (upadacitinib; 15 mg, once-daily) achieved the primary endpoint of ASAS40 response in adult patients with active ankylosing spondylitis (AS) at 14 weeks versus placebo[1]
-
November 08, 2019- Application is being reviewed under the FDA's Real-Time Oncology Review pilot program
-
November 06, 2019
-
November 04, 2019- Data include first presentation of the SELECT-AXIS 1 Phase 2/3 study evaluating upadacitinib in patients with active ankylosing spondylitis
-
November 01, 2019- Reports Third-Quarter Diluted EPS of $1.26 on a GAAP Basis; Adjusted Diluted EPS of $2.33
-
October 31, 2019- Positive top-line study results show that both doses of RINVOQ™ (upadacitinib; 15 mg and 30 mg, once daily) met the primary endpoint of ACR20 response in adult patients with active psoriatic arthritis who had an inadequate response to other bDMARDs at week 12 versus placebo[1]
-
October 29, 2019- Let Me Be Clear is a digital empowerment platform for people with psoriasis to share their experiences and aspirations and learn how to achieve the best care
-
October 24, 2019
-
October 18, 2019- CHMP positive opinion, supported by data from the pivotal Phase 3 SELECT rheumatoid arthritis program evaluating more than 4,400 patients, will now be referred to the European Commission for final approval[1-5]
-
October 09, 2019- Twenty new abstracts underscore AbbVie's commitment to advancing standards of care for people living with serious skin diseases
-
October 08, 2019
-
September 27, 2019NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
-
September 26, 2019- MAVYRET® (glecaprevir/pibrentasvir) is now available as the only 8-week pan-genotypic treatment option for treatment-naïve chronic hepatitis C (HCV) patients, without cirrhosis or with compensated cirrhosis* †
-
September 23, 2019- Final data from Phase 1b study evaluating subcutaneous infusion of investigational medicine ABBV-951 in patients with advanced Parkinson's disease (PD) to be presented as late breaker
-
September 06, 2019
-
August 29, 2019- MERU, a Phase 3 placebo-controlled trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit for patients receiving Rova-T at the interim analysis
-
August 27, 2019
-
August 16, 2019- RINVOQ (upadacitinib) met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis[1-7]
-
August 05, 2019- New Drug Application (NDA) is supported by data from pivotal Phase 3 studies of nearly 800 patients
-
July 26, 2019- Announced a Definitive Transaction Agreement to Acquire Allergan, Significantly Expanding and Diversifying AbbVie's Revenue Base with New Therapeutic Areas and Enhancing Long-Term R&D Funding Capacity to Allow for Continued Investment in Innovative Science
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
